Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation

Completed · Phase 2

Conditions studied: Non-Hodgkin's Lymphoma, Multiple Myeloma

In brief

This protocol will investigate the effectiveness of plerixafor in the up-front setting in avoiding a second round of mobilization and whether this translates into a clinical and economic benefit.

Key facts

Study ID

NCT01339572

Run by

University of Florida

People needed

72

Starts

2011-04-01

Expected to finish

2015-11-01

Last updated by the study team

2017-08-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with multiple myeloma or non-Hodgkin's lymphoma with a planned autologous transplant and who are eligible for peripheral stem cell mobilization.
• Karnofsky Performance Status ≥ 70.
• Age ≥ 18
• Less than 30% involvement of marrow with disease.

You may not qualify if…

• > 30% marrow involvement with disease
• Age < 18.
• Pregnant women.

Where it is running

• Shands Cancer Hospital at the University of Florida — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.